ralimetinib

Ralimetinib selectively inhibits phosphorylation of MK2 (Thr334) and has no effect on phosphorylation of p38α MAPK, JNK, ERK1 2, c-Jun, ATF2, or c-Myc. Ralimetinib is an effective and selective, ATP-competitive inhibitor of p38 MAPK α β (IC50s: 5.3 and 3.

Ralimetinib dimesylate (LY2228820 dimesylate) 是一种选择性，ATP 竞争性的 p38 MAPK α β抑制剂，IC50分别为5.3 和 3.2 nM。